GÜRBÜZ, M. Et Al. 2022. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group. MEDICINE , vol.101, no.50 .

GÜRBÜZ, M., Kilickap, S., BİLİCİ, A., Karadurmus, N., Sezer, A., ŞENDUR, M. A. N., ... PAYDAŞ, S.(2022). Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group. MEDICINE , vol.101, no.50.

GÜRBÜZ, MUSTAFA Et Al. "Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group," MEDICINE , vol.101, no.50, 2022

GÜRBÜZ, MUSTAFA Et Al. "Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group." MEDICINE , vol.101, no.50, 2022

GÜRBÜZ, M. Et Al. (2022) . "Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group." MEDICINE , vol.101, no.50.

@article{article, author={MUSTAFA GÜRBÜZ Et Al. }, title={Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group}, journal={MEDICINE}, year=2022}